
A Novo Nordisk drug, IDegLira which combines its long-acting insulin degludec with its type 2 diabetes treatment Victoza, maintained superior blood sugar reduction after one year.
A Novo Nordisk drug, IDegLira which combines its long-acting insulin degludec with its type 2 diabetes treatment Victoza, maintained superior blood sugar reduction after one year.